AbCellera Biologics
ABCL | NASDAQ
$11.12
-$0.37 (-3.22%)
At close: Nov 16, 2026, 4:00 PM ET
$11.13
+$0.01 (+0.09%)
After-hours:
Nov 16, 2026, 7:53 PM ET
AbCellera Biologics Company Profile
Company profile explainedCompany Profile
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Key Executives
| Name | Position |
|---|---|
| Carl Hansen | Chief Executive Officer, President & Chairperson |
| Andrew Booth | Chief Financial Officer |
| Tryn T. Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer |
| Veronique Lecault | Chief Technology Officer & Director |
| Adam Clarke | Senior Vice President of Discovery |
| Andrew Knowles | Vice President of Operations |
| Caitlin Webster CIPD | Director of Talent Development |
| Marcie Thiessen | Senior Director of Finance & Accounting |
| Martin Hogan | Senior Director of Strategic Finance & IR |
| Murray McCutcheon | Senior Vice President of Partnering |
| Tiffany Chiu | Vice President of Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 24, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 424B5 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 11, 2026 | 424B5 | Filing |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 8-K | Current Report |
AbCellera Biologics
| Country | Canada |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 562 |
| CEO | Carl Hansen |
Stock Details
| Ticker Symbol | ABCL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001703057 |
| CUSIP Number | 00288U106 |
| ISIN Number | CA00288U1066 |
| SIC Code | 2834 |
Recent News
- 9 hours ago / marketbeat.comAbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment
- 3 days ago / seekingalpha.comAbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
- 4 days ago / zacks.comAre Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
- 4 days ago / marketbeat.comAbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results
- 7 days ago / seekingalpha.comAbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
- 7 days ago / marketbeat.comWhat AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call
- 7 days ago / zacks.comAbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
- 1 month ago / businesswire.comAbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
- 2 months ago / businesswire.comAbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
- 2 months ago / zacks.comABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
Add to Watchlist
Select watchlists to add or remove ABCL